Esta página web solamente está disponible en ingles en este momento. Apreciamos su paciencia mientras traducimos el contenido de nuestra página.
Sharing science to understand Long COVID
RECOVER Research Review (R3) Seminar Series
The goal of the R3 Seminar Series is to share the RECOVER Initiative’s research findings with researchers and the public. These seminars accelerate scientific discovery by allowing experts to share their latest insights on Long COVID and related conditions. Some R3 sessions also inform the public about other research on Long COVID. You can find recordings of all R3 Seminar sessions in the Previous Seminars section below.
Effectiveness of Paxlovid in Protecting Against Long COVID: EHR Insights
Speakers will present findings from two studies examining whether Paxlovid treatment in the acute phase of COVID-19 helps to prevent Long COVID. The study teams used electronic health records from the National Covid Cohort Collaborative (N3C) and the National Patient-Centered Clinical Research Networks (PCORnet) RECOVER repository.
The speakers presented research to investigate clinical laboratory markers of COVID and Long COVID. They also discussed an update of the Long COVID research index based on additional patient data and how researchers can use the index to identify people with Long COVID and its symptom subtypes.
During the January 28th RECOVER Research Review (R3) Seminar, Dr. Kellie Owens, PhD (NYU Grossman School of Medicine) shared ethical guidance for enrolling individuals in clinical studies who have direct involvement with the research. Dr. Owens was joined by co-authors Leah Castro, MA (RECOVER Community and Caregiver Representative) and Rebecca Letts (RECOVER Patient and Caregiver Representative), who described Representatives’ important role in designing RECOVER clinical studies and developing peer-reviewed research publications.
During the December 10th RECOVER Research Review (R3) Seminar, researchers described a recent pathobiology study investigating viral persistence, or when SARS-CoV-2 remains in a person’s body and continues to cause changes even after they recover from their initial sickness. The study’s findings suggest that viral persistence could be one reason why some people experience certain symptoms of Long COVID.
During the November 12th RECOVER Research Review (R3) Seminar, researchers described how they are studying people’s health and habits both before and during the pandemic to answer important questions about COVID-19 and its long-term effects. Specifically, two studies using data collected by the Collaborative Cohort of Cohorts for COVID-19 Research (C4R) have identified several different factors that could impact the protective effects of COVID-19 vaccines.
By reviewing patient medical records from as early as March 2020, the findings from these studies provide insights into potential risks associated with developing Long COVID.
During the October 8th RECOVER Research Review (R3) Seminar, researchers described how RECOVER and the All of Us Research Program collaborate to advance our understanding of Long COVID. These different National Institutes of Health (NIH) initiatives are sharing health data and developing innovative tools to gain important insights from that data.
During the September 10th RECOVER Research Review (R3) Seminar, RECOVER researchers presented some early findings from the RECOVER Pediatric Observational Cohort study. They presented a symptom-based approach for identifying children and adolescents with Long COVID from a study published in JAMA.
During the June 25th RECOVER Research Review (R3) Seminar, researchers presented details about RECOVER-SLEEP, which included two trials focused on identifying potential treatments for sleep disturbances. Researchers also shared details about RECOVER-ENERGIZE, which included one trial focused on potential treatments for exercise intolerance and one trial examining potential treatments for post-exertional malaise. All the trials were recruiting adults experiencing one or more of these symptoms after having COVID. The presentation also included updates on other RECOVER clinical trials in progress.
View